Bioxytran Innovates with Camel Hemoglobin as a Universal Oxygen Carrier
Bioxytran, Inc. (OTCQB: BIXT) is making strides in the biotechnology sector by securing a GMP quality source of camel hemoglobin, a significant advancement for its efforts to create a new type of oxygen transport technology.
Collaboration with the Heme Foundation
In partnership with the Heme Foundation, Bioxytran is embarking on a $10 million joint venture aimed at developing a Universal Oxygen Carrier (UOC). This collaboration is a crucial step in addressing severe blood shortages around the globe and aims to revolutionize medical practice by providing an alternative for blood transfusions.
Benefits of Camel Hemoglobin
Camel hemoglobin is emerging as an exceptional component for the UOC project due to its unique properties. Unlike cow hemoglobin, camel hemoglobin does not present the same risks linked to transmissible diseases. This reliability, combined with a longer half-life, increases its viability in clinical applications.
Resilience of Camel Hemoglobin
Camels, known for their ability to thrive in extreme environments, provide hemoglobin that remains highly effective under challenging conditions, such as elevated temperatures or high salt concentrations. The adaptability of camel hemoglobin results in a more stable molecule compared to its bovine counterpart, ensuring a consistent performance as an oxygen carrier.
Long-term Vision for Bioxytran
This supply of camel hemoglobin is more than just a short-term solution; it aims to enhance Bioxytran's long-term research and development strategy. Under the joint venture's terms, Bioxytran retains full intellectual property rights, which can lead to significant advancements in their leading oxygen transport molecule, BXT-25. This product is posited to improve treatment outcomes for multiple medical conditions, including Alzheimer's disease and strokes.
Leadership's Perspective
David Platt, CEO of Bioxytran, expressed enthusiasm about the agreement, highlighting its potential to attract funding and accelerate the groundbreaking work being done in oxygen delivery technology. With a reliable supplier, the company is set to explore more innovative solutions in this critical area.
About the Heme Foundation
The Heme Foundation, established as a nonprofit in 2021, plays a pivotal role in this initiative. Its mission focuses on finding effective alternatives to blood transfusions, thereby streamlining the complex logistics involved with traditional blood supplies.
About Bioxytran, Inc.
Bioxytran, Inc. is at the cutting-edge of biotechnology, concentrating on complex carbohydrate-based therapeutics. The company's work addresses significant medical challenges in virology, oncology, and oxygen transport, with ongoing programs targeting pulmonary fibrosis and stroke treatments.
For questions or to learn more about their initiatives, interested parties can reach out to the investor relations team directly.
Frequently Asked Questions
What is the significance of camel hemoglobin for Bioxytran?
Camel hemoglobin provides a stable and risk-free option for creating a Universal Oxygen Carrier, vital for new treatment developments.
How does the partnership with the Heme Foundation benefit Bioxytran?
The collaboration offers access to resources and expertise aimed at solving blood supply issues, enhancing Bioxytran's research capabilities.
What medical conditions does BXT-25 aim to address?
BXT-25 is developed to assist in treating conditions such as strokes, traumatic brain injuries, and Alzheimer’s disease.
Why is camel hemoglobin preferred over cow hemoglobin?
Camel hemoglobin presents fewer health risks and exhibits greater stability and efficiency in oxygen transport, particularly under extreme conditions.
What future advancements can be anticipated from this supply agreement?
The agreement may open up new funding avenues and research opportunities, fostering innovation in oxygen transport technology.
